DCF Valuation
ProQR Therapeutics BV (PRQR) DCF Valuation — Is PRQR undervalued?
The estimated DCF fair value of one ProQR Therapeutics BV (PRQR) share is $2.30. Compared to the current market price of $1.97, the stock is undervalued by 16.9%.
DCF fair value
$2.30
Market price
$1.97
Upside / downside
+16.9%
Prefer the inverse question? See what growth rate the market is pricing into PRQR →
ProQR Therapeutics BV (PRQR) DCF valuation FAQ
What is the DCF fair value of ProQR Therapeutics BV (PRQR)?
The discounted-cash-flow model estimates the intrinsic fair value of one ProQR Therapeutics BV (PRQR) share at $2.30, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is ProQR Therapeutics BV (PRQR) overvalued or undervalued?
Against the current market price of $1.97, the DCF fair value of $2.30 implies PRQR is undervalued by 16.9%.
How is the PRQR DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from ProQR Therapeutics BV's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when ProQR Therapeutics BV files a new quarterly or annual report.
How this PRQR valuation is built
The model projects ten years of ProQR Therapeutics BV's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing ProQR Therapeutics BV's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when ProQR Therapeutics BV files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.